| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$92 |
Corporate Governance Statement
|
30 Aug 2024 9:15AM |
$0.042 |
$0.029 |
fallen by
30.95%
|
|
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$7,763 |
Results Announcement for FY24
|
30 Aug 2024 9:15AM |
$4.890 |
$6.230 |
risen by
27.40%
|
|
HVN - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong operating cash flows of $686.53 million at a cash conversion rate of 100.4%
- Net assets increased to $4.54 billion
- Total system sales revenue reached $8.86 billion
- Reported profit before tax (PBT) was $541.69 million, a 30.2% decrease from FY23
- Emerging AI-PC market expected to drive future sales growth
- Significant reduction in net debt to equity ratio to 14.49%
- Maintained a solid asset base of nearly $8 billion
- Emphasis on omni-channel strategy to leverage brand and geographical reach
- Home Appliances, Mobile & Computer Technology categories poised for growth in FY25 and beyond
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$92 |
ACW FY2024 results, advancing into late-stage trials
|
30 Aug 2024 9:14AM |
$0.042 |
$0.029 |
fallen by
30.95%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical (ACW) is an ASX-listed biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases.
- Their lead compound, Xanamem, targets the inhibition of cortisol production in the brain, potentially benefiting conditions like Alzheimer's Disease and Depression.
- The XanaCIDD Phase 2a trial showed promising results on depression and cognitive function.
- The XanaMIA Phase 2b Alzheimer's disease trial aims to assess Xanamem's effects on cognition and disease progression.
- The company received a UK Innovation Passport for Xanamem in Alzheimer's treatment.
- Statutory financial results for FY2024 showed a net loss of $13,044,282, with significant investments in R&D.
- Key highlights include the start of new clinical sites in Australia and the US for the XanaMIA trial.
- Future plans include longer treatment periods for depression trials and potential Phase 2b trials starting in mid-2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cape Range Ltd (CAG) ORDINARY FULLY PAID |
Information Technology |
- |
Appendix 4D and 30 June 2024 Half Year Financial Statements
|
30 Aug 2024 9:14AM |
$0.190 |
$0.090 |
fallen by
52.63%
|
|
CAG - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues from ordinary activities increased by 14% to A$294,000.
- Loss from ordinary activities after tax reduced by 30% to A$211,000.
- No dividends were declared for the half year ended 30 June 2024.
- Net tangible assets per ordinary share decreased to 1.6 cents from 2.0 cents in the previous period.
- The company did not gain or lose control over any entities during the reporting period.
- No associates or joint venture entities are reported.
- An impairment charge of $86,823 was recorded.
- Cash and cash equivalents decreased to A$1,708,361 from A$1,902,149 at the beginning of the period.
- No significant subsequent events affecting the company's operations were reported.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Artrya Limited (AYA) ORDINARY FULLY PAID |
Health Care |
$237 |
Appendix 4E and Annual Financial Statements June 2024
|
30 Aug 2024 9:14AM |
$0.320 |
$2.040 |
risen by
537.50%
|
|
AYA - Price-sensitive ASX Announcement
Full Release
Key Points
- Artrya Limited focused on developing AI platform Salix for coronary artery disease.
- Loss for the year ended June 30, 2024, increased by 25.7% to $14 million.
- No dividends were paid, recommended, or declared during the financial period.
- Cash balance at the end of the financial year was $7.1 million, down from $20.1 million the previous year.
- FDA 510(k) clearance for Salix Coronary Anatomy product expected in first half of FY25.
- First commercial agreement in Australia with The Cardiac Centre NSW, revenue expected in Q1 FY25.
- Strategic partnership agreements in the US with Northeast Georgia Health Ventures, Tanner Health System, and Cone Health.
- Operating cash outflows for the year amounted to $15.41 million.
- Total net assets decreased from $30.6 million to $16.8 million.
- Investment in Salix platform to improve detection and treatment of coronary artery disease.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$7,763 |
Presentation of Results for FY24
|
30 Aug 2024 9:14AM |
$4.890 |
$6.230 |
risen by
27.40%
|
|
HVN - Price-sensitive ASX Announcement
Full Release
Key Points
- Net assets increased by $70.44 million (+1.6%) from June 2023.
- Substantial growth of 41.9% in net assets since June 2019.
- Operating cash flows rose by $6.27 million to $686.53 million.
- Reported profit before tax (PBT) declined by $234.39 million (-30.2%) from FY23.
- Total revenue decreased by $165.21 million (-3.9%) from FY23.
- Decrease in franchise fees due to a reduction in aggregated franchisee sales revenue.
- Increase in company-operated sales revenue by $27.29 million.
- Cost of sales increased by $46.91 million (+2.5%) due to new overseas stores.
- Operating expenses rose by $25.01 million (+1.5%) due to inflation and new store openings.
- Effective tax rate was higher at 33.98% for FY24 due to a deferred tax expense in New Zealand.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nickelx Limited (NKL) ORDINARY FULLY PAID |
Materials |
- |
Proposed issue of securities - NKL
|
30 Aug 2024 9:14AM |
$0.020 |
$0.029 |
risen by
45%
|
|
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$7,763 |
Dividend/Distribution - HVN
|
30 Aug 2024 9:14AM |
$4.890 |
$6.230 |
risen by
27.40%
|
|
| US Masters Residential Property Fund (URF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$214 |
Update - Notification of buy-back - URF
|
30 Aug 2024 9:14AM |
$0.310 |
$0.310 |
fallen by
0%
|
|
| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$37 |
Update - Notification of buy-back - MEC
|
30 Aug 2024 9:14AM |
$0.980 |
$1.135 |
risen by
15.82%
|
|
| Nickelx Limited (NKL) ORDINARY FULLY PAID |
Materials |
- |
Acquisition of Penny South Gold Project, WA
|
30 Aug 2024 9:14AM |
$0.020 |
$0.029 |
risen by
45%
|
|
NKL - Price-sensitive ASX Announcement
Full Release
Key Points
- Binding Tenement Sale Agreement to acquire 100% of Penny South Gold Project (E57/1045).
- Located 550m south of Penny West/North Gold Mine.
- The project includes a ~2.5km strike of the Penny West Shear.
- Historical drilling indicates significant gold mineralisation.
- NickelX will pay $60,000 in cash and issue 3,000,000 shares.
- Deferred payments based on achieving certain resource milestones.
- Planned detailed geological review and deeper drilling.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Washington H. Soul Pattinson and Co. Limited (SOL) ORDINARY FULLY PAID |
Financials |
$15,899 |
Placement Cleansing Notice
|
30 Aug 2024 9:13AM |
$34.330 |
$43.220 |
risen by
25.90%
|
|
| Future Generation Australia Limited (FGX) ORDINARY FULLY PAID |
Financials |
$541 |
Appendix 4D and Financial Report
|
30 Aug 2024 9:13AM |
$1.230 |
$1.320 |
risen by
7.32%
|
|
FGX - Price-sensitive ASX Announcement
Full Release
Key Points
- The half-year financial report for Future Generation Australia Limited was reviewed, showing a financial position as at 30 June 2024.
- The pre-tax Net Tangible Assets (NTA) increased by 5.4% in the six months to 30 June 2024.
- Total shareholder return (TSR) for the six-month period was 9.8%, or 11.1% including the value of franking credits.
- An increased fully franked interim dividend of 3.5 cents per share was declared.
- Net profit for the period was $23.3 million, up from $20.8 million in the previous corresponding period.
- Operating profit before tax was $29.6 million, an 18.2% increase from the previous period.
- The investment portfolio outperformed with a 6.0% increase during the period, contributing to the financial results.
- The company's activities include investing in Australian equity funds and contributing to Australian children and youth at risk social impact partners.
- The company’s principal activity and investment strategy remained unchanged during the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$7,763 |
FY24 Annual Report and Appendix 4E
|
30 Aug 2024 9:13AM |
$4.890 |
$6.230 |
risen by
27.40%
|
|
HVN - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported profit before tax for FY24 was $541.69 million, down by $234.39 million (–30.2%) from FY23.
- Total revenues for FY24 were $4.11 billion, a decline of $165.21 million (–3.9%) compared to FY23.
- Harvey Norman has a strong balance sheet with total assets of nearly $8 billion and net assets of $4.54 billion as of 30 June 2024.
- The company has invested in Generative AI product cycles and technological upgrades to support franchisees and company-operated stores.
- Revenues from franchisees decreased by $91.63 million (–7.8%) in FY24.
- Company-operated sales revenue increased by $27.29 million due to overseas expansion.
- Operating cash flows for FY24 were $686.53 million with a cash conversion ratio of 100.4%.
- Despite challenging retail conditions, the company has continued to invest in store expansions and refits.
- The company plans to open 10 new stores in Malaysia by the end of FY25.
- Harvey Norman has a diversified strategy encompassing retail, franchise, property, and digital systems across key home and consumer lifestyle product categories.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rhythm Biosciences Limited (RHY) ORDINARY FULLY PAID |
Health Care |
$28 |
Appendix 4G
|
30 Aug 2024 9:13AM |
$0.067 |
$0.100 |
risen by
49.25%
|
|
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$20 |
Preliminary Final Report - Appendix 4E
|
30 Aug 2024 9:13AM |
$0.021 |
$0.012 |
fallen by
42.86%
|
|
LIT - Price-sensitive ASX Announcement
Full Release
Key Points
- Lithium Australia's FY24 revenue increased to $6.7 million, primarily from its recycling division.
- The company reported a gross profit of $2.2 million, an improvement from the previous year's $1.5 million.
- A significant provision of $4.1 million was made for remediation related to a fire incident in January 2019.
- The company signed several important agreements, including a joint development agreement with Mineral Resources Ltd. to commercialize the LieNA® lithium extraction technology.
- Lithium Australia entered into MoUs with First Phosphate Corp. and Centrex Limited for potential development of LFP and LMFP cathode active material manufacturing plants.
- The company announced a capital raising of up to $7.5 million, with an initial $1.8 million secured.
- Envirostream, a subsidiary, achieved a milestone by delivering positive operating profits in Q4 FY24.
- Despite increased revenue and gross profit, the company reported a net loss of $10.8 million, up from $7.4 million in the previous year.
- There was a significant decrease in net assets from $17.3 million in 2023 to $3.3 million in 2024.
- The company is focusing on sustaining positive operating cashflows, securing further recycling agreements, and progressing its lithium phosphate production.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$78 |
1H24 - Appendix 4D
|
30 Aug 2024 9:12AM |
$0.090 |
$0.515 |
risen by
472.22%
|
|
EDU - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations increased by 66% from the previous corresponding period.
- EBITDA grew significantly by 848%, reaching $2,250,252.
- EBIT turned positive from a loss of $1,563,854 to $704,345.
- The company reported a net profit after tax attributable to members of $28,484, reversing a loss of $1,551,279.
- There was no gain on the disposal of the Investment in Associate in the current period, compared to $179,658 in the previous period.
- Net tangible asset backing per ordinary share decreased to (4.29) cents from (2.83) cents.
- No control was gained or lost over entities during the period.
- No dividend was paid or proposed during the period.
- There were no associates or joint ventures during the period.
- The consolidated entity’s Half-Year Report contains an independent auditor’s review report that is not subject to a modified conclusion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Incitec Pivot Limited (IPL) ORDINARY FULLY PAID |
Materials |
$4,827 |
Update - Notification of buy-back - IPL
|
30 Aug 2024 9:12AM |
$3.010 |
$2.590 |
fallen by
13.95%
|
|
| Acrow Limited (ACF) ORDINARY FULLY PAID |
Industrials |
$313 |
Change of Company Secretary and Registered Office
|
30 Aug 2024 9:12AM |
$0.950 |
$1.015 |
risen by
6.84%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$92 |
ACW Appendix 4E and 2024 Annual Report
|
30 Aug 2024 9:12AM |
$0.042 |
$0.029 |
fallen by
30.95%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited focuses on developing Xanamem for Alzheimer’s disease and depression
- Xanamem is a brain tissue cortisol synthesis inhibitor
- Xanamem trials show promising results in reducing cortisol levels in patients
- Actinogen completed two major Phase 2 trials for Xanamem in depression and Alzheimer’s disease
- The Company received a UK Innovation Passport for Xanamem
- Actinogen presented at major conferences to build relationships and share findings
- The financial year 2024 saw significant milestones in Xanamem’s clinical development
- Actinogen raised $18.9 million through capital raisings and received additional funding from R&D tax incentives
- The Company plans to accelerate Phase 2b trials for Alzheimer’s and depression in 2025
- The annual report includes financial statements, board of directors’ reviews, and future outlook
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sports Entertainment Group Limited (SEG) ORDINARY FULLY PAID |
Communication Services |
$89 |
SEG FY24 Results Announcement
|
30 Aug 2024 9:11AM |
$0.300 |
$0.320 |
risen by
6.67%
|
|
SEG - Price-sensitive ASX Announcement
Full Release
Key Points
- FY24 revenue from continuing operations was $124.6 million, a 10.8% increase from the prior period.
- The Australian business experienced robust revenue growth, particularly from complementary services divisions.
- Digital audience consumption was strong with 1.2 million monthly average users.
- Underlying EBITDA for FY24 was $7.4 million, a 14.6% increase from the prior period.
- The sale of the SENZ audio and digital business impacted the overall financials.
- SEG completed Stage 1 of the Perth Wildcats sale, resulting in $21 million of net cash inflows.
- Debt was reduced significantly to $13.3 million from $22.8 million in the previous year.
- A fully franked special dividend of 2 cents per share was declared, payable on 3 October 2024.
- Operational costs increased but are expected to normalize and reduce in FY25.
- SEG's strategy involves continuing to build its asset base with minor acquisitions and focusing on cost governance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Firstwave Cloud Technology Limited (FCT) ORDINARY FULLY PAID |
Information Technology |
$26 |
Preliminary Final Report
|
30 Aug 2024 9:11AM |
$0.019 |
$0.015 |
fallen by
21.05%
|
|
FCT - Price-sensitive ASX Announcement
Full Release
Key Points
- Directors were John Grant, Danny Maher, Daniel Friel, Ray Kiley, Paul MacRae, and Euh (David) Hwang.
- Principal activities include development and sale of network monitoring and internet security software.
- No dividends paid, recommended, or declared during the financial year.
- Loss after income tax amounted to $23,040,028, including an impairment of intangible assets of $19,955,063.
- Acquisition of Saisei Networks Inc. included issuing 40,571,428 new shares and $200,000 in cash receivables.
- Expected benefits from Saisei acquisition include expanding IP, improving NMIS functionality, gaining new clients, and increasing annual revenue by approximately $1 million.
- Management restructuring included appointing Iain Bartram as interim COO and focusing CEO Danny Maher on sales and strategic goals.
- Key sales included extensions with NASA and Telmex, and a new reseller agreement with Telmex.
- Net assets decreased to $32,212,626 from $52,430,106.
- Total equity consisted of issued capital of $131,001,770, reserves of $5,783,561, and accumulated losses of $104,572,705.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rhythm Biosciences Limited (RHY) ORDINARY FULLY PAID |
Health Care |
$28 |
RHY Financial Report FY2024
|
30 Aug 2024 9:11AM |
$0.067 |
$0.100 |
risen by
49.25%
|
|
| Sports Entertainment Group Limited (SEG) ORDINARY FULLY PAID |
Communication Services |
$89 |
Preliminary Final Report
|
30 Aug 2024 9:10AM |
$0.300 |
$0.320 |
risen by
6.67%
|
|
SEG - Price-sensitive ASX Announcement
Full Release
Key Points
- Preliminary Final Report of Sports Entertainment Group Limited for the financial year ended 31 March 2024
- Details on the company's financial performance and operational highlights
- Significant growth in revenue and earnings across multiple segments
- Increase in audience reach and expansion of digital platforms
- Strategic acquisitions bolstered the company's market position
- Future growth initiatives and outlook for the next financial year
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strike Energy Limited (STX) ORDINARY FULLY PAID |
Energy |
$396 |
Trading Halt
|
30 Aug 2024 9:09AM |
$0.195 |
$0.120 |
fallen by
38.46%
|
|
STX - Price-sensitive ASX Announcement
Full Release
Key Points
- Strike Energy Limited (STX) requested a trading halt.
- The trading halt is to manage continuous disclosure obligations.
- The reason for the trading halt is related to the Erregulla Deep 1 well drilling results.
- The trading halt will be in effect until the earlier of normal trading on 3 September 2024 or the announcement release.
- Strike Energy Limited is not aware of any reason against the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
